Merck Clinical Trials Logo Merck Clinical Trials

Clinical Trials

Merck Clinical Trials
  • About clinical trials
    • About Clinical Trials
    • How does participation work?
    • What to consider
    • Frequently asked questions
  • Resources
    • Resources
    • For patients
    • For caregivers
  • Our medical science
  • For HCPs
  • English
    • Back
    • English
    • Español

Study Keyword: Infections

This is a phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nosocomial pneumonia (NP).

Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia

August 30, 2022

By clique_admin

This is a phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nosocomial pneumonia (NP).

Clesrovimab in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus Disease

February 24, 2022

By clique_admin

This study aims to evaluate the safety and tolerability of clesrovimab compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Gram-negative Bacterial Infection

December 8, 2021

By clique_admin

The primary purpose of this study is to evaluate the safety and tolerability of imipenem/cilastatin/relebactam (IMI/REL) in participants from birth to less than 18 years of age with confirmed or suspected

Posaconazole Intravenous and Oral in Children With Invasive Fungal Infection

October 15, 2021

By clique_admin

This study aims to estimate the pharmacokinetics (PK) of posaconazole (POS, MK-5592) intravenous (IV) and powder for oral suspension (PFS) formulations in pediatric participants

Posaconazole Intravenous and Oral in Children With Invasive Aspergillosis

October 13, 2021

By clique_admin

This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to

Doravirine in Human Immunodeficiency Virus -Infected Children Ages 4 Weeks to <12 Years and <45 kg

October 13, 2021

By clique_admin

This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 weeks to

Merck Clinical Trials Logo Merck Clinical Trials
  • Merck.com
  • Privacy Policy
  • Terms of Use
  • Policies & Perspectives
  • Cookie Preferences
  • Accessibility

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

THIS WEBSITE IS INTENDED FOR A UNITED STATES AUDIENCE ONLY

Merck Essential Accessibility

Merck Essential Accessibility